Iron chelation beyond transfusion iron overload
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The effects of systemic iron overload in hereditary (e.g., classic HFE hemochromatosis) or acquired disorders (e.g., transfusion-dependent iron overload) are well known. Several other iron overload diseases, with an observed mild-to-moderate increase in iron in selected organs (e.g., the liver or the brain), or with "misdistribution" of iron within cells (e.g., reticuloendothelial cells) or subcellular organelles (e.g., mitochondria), have been recognized more recently. The deleterious impact of any excess iron may be high as active redox iron may directly contribute to cell damage or affect signaling pathways involved in cell necrosis-apoptosis or organ fibrosis and cancer. This article discusses the potential use of iron chelation therapy to treat iron overload from causes other than transfusion overload.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sattar, N., Gaw, A., Scherbakova, O., Ford, I., O’Reilly, D. S. J., Haffner, S. M., Isles, C., Macfarlane, P. W., Packard, C. J., Cobbe, S. M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000080897.52664.94 · Cited by 1,506
Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07264.x · Cited by 1,149
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Kalinowski, D. S., & Richardson, D. R. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.4.2 · Cited by 721
Hunt, K. J., Resendez, R. G., Williams, K., Haffner, S. M., & Stern, M. P. (2004) · Circulation · doi:10.1161/01.cir.0000140762.04598.f9 · Cited by 662 · cited 1×
“NAFLD has been shown to be an important predictor of Type 2 diabetes [35–38] and cardiovascular disease [39].”
BackgroundComponents of the “Metabolic Syndrome” and Incidence of Type 2 Diabetes
Hanson, R. L., Imperatore, G., Bennett, P. H., & Knowler, W. C. (2002) · Diabetes · doi:10.2337/diabetes.51.10.3120 · Cited by 590
Hirsch, E. C., Brandel, J. ‐., Galle, P., Javoy‐Agid, F., & Agid, Y. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb08170.x · Cited by 537
The role of iron in cell cycle progression and the proliferation of neoplastic cells
Le, N. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00068-9 · Cited by 453
The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy
Gaeta, A., & Hider, R. C. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706416 · Cited by 411 · cited 1×
“Protein aggregation and oxidative stress have been demonstrated as important factors leading to the pathogenesis of neurodegenerative processes in Alzheimer’s disease, Parkinson’s disease, and prion disease [53].”
BackgroundSelective iron chelation in Friedreich ataxia: biologic and clinical implications
Boddaert, N., Le Quan Sang, K. H., Rötig, A., Leroy-Willig, A., Gallet, S., Brunelle, F., Sidi, D., Thalabard, J.-C., Munnich, A., & Cabantchik, Z. I. (2007) · Blood · doi:10.1182/blood-2006-12-065433 · Cited by 409
An introduction to the free radical hypothesis in Parkinson's disease
Olanow, C. W. (1992) · Annals of Neurology · doi:10.1002/ana.410320703 · Cited by 382
Cited by
Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents
Nucci, M., & Anaissie, E. (2009) · Clinical Infectious Diseases · doi:10.1086/605664 · Cited by 347
Labile iron in cells and body fluids: Physiology, pathology, and pharmacology
Cabantchik, Z. I. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00045 · Cited by 306
Miura, K., Taura, K., Kodama, Y., Schnabl, B., & Brenner, D. A. (2008) · Hepatology · doi:10.1002/hep.22486 · Cited by 270
An update on iron chelation therapy.
(2012) · Europe PMC (PubMed Central) · doi:10.2450/2012.0008-12 · Cited by 233
Design of iron chelators with therapeutic application
Zhou, T., Ma, Y., Kong, X., & Hider, R. C. (2012) · Dalton Transactions · doi:10.1039/c2dt12159j · Cited by 136
Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells
Hou, W.-H., Rossi, L., Shan, Y., Zheng, J.-Y., Lambrecht, R. W., & Bonkovsky, H. L. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.4499 · Cited by 35
Metadata
- Authors
- Pietrangelo, A.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2007-12
- Volume
- 82
- Issue
- S12
- Pages
- 1142-1146
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W1989037755
- Cited by
- 38
- References
- 12
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.